Evidence map›Paper›PMID 32143367›Full record

ArticleCells2020

BMP-9 Modulates the Hepatic Responses to LPS.

Haristi Gaitantzi, Julius Karch, Lena Germann, Chen Cai, Vanessa Rausch, Emrullah Birgin, Nuh Rahbari, Tatjana Seitz, Claus Hellerbrand, Courtney König and 8 more

Open access · goldAbstract read
In one paragraph

Article in Cells, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Liver diseases: epidemiology, causes, trends and predictions.Signal transduction and targeted therapy · 2025
    Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. New insights into BMP9 signaling in liver diseases.Molecular and cellular biochemistry · 2021
    Review
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 4 institutions in 1 country.

Haristi GaitantziDepartment of Medicine II, Medical Faculty Mannheim, Heidelberg University, 68167 Mannheim, Germany.
Julius KarchDepartment of Medicine II, Medical Faculty Mannheim, Heidelberg University, 68167 Mannheim, Germany.
Lena GermannDepartment of Medicine II, Medical Faculty Mannheim, Heidelberg University, 68167 Mannheim, Germany.
Chen CaiDepartment of Medicine II, Medical Faculty Mannheim, Heidelberg University, 68167 Mannheim, Germany.
Vanessa RauschCenter for Alcohol Research, University of Heidelberg and Salem Medical Center, 69120 Heidelberg, Germany.
Emrullah BirginDepartment of Surgery, University Medicine Mannheim, Medical Faculty Mannheim, Heidelberg University, 68167 Mannheim, Germany.ORCID 0000-0002-0338-3727
Nuh RahbariDepartment of Surgery, University Medicine Mannheim, Medical Faculty Mannheim, Heidelberg University, 68167 Mannheim, Germany.
Tatjana SeitzInstitute of Biochemistry, Emil-Fischer-Zentrum, Friedrich-Alexander-University Erlangen-Nürnberg, 91054 Erlangen, Germany.
Claus HellerbrandInstitute of Biochemistry, Emil-Fischer-Zentrum, Friedrich-Alexander-University Erlangen-Nürnberg, 91054 Erlangen, Germany.
Courtney KönigDivision of Vascular Oncology and Metastasis, German Cancer Research Center Heidelberg (DKFZ-ZMBH Alliance), 69120 Heidelberg, Germany.
Hellmut G AugustinDivision of Vascular Oncology and Metastasis, German Cancer Research Center Heidelberg (DKFZ-ZMBH Alliance), 69120 Heidelberg, Germany.ORCID 0000-0002-7173-4242
Carolin MoglerInstitute of Pathology, Technical University of Munich, 80333 Munich, Germany.
Carolina de la TorreMedical Faculty Mannheim, Medical Research Center, Heidelberg University, 68167 Mannheim, Germany.ORCID 0000-0001-8918-2266
Norbert GretzMedical Faculty Mannheim, Medical Research Center, Heidelberg University, 68167 Mannheim, Germany.
Timo ItzelDepartment of Medicine II, Medical Faculty Mannheim, Heidelberg University, 68167 Mannheim, Germany.
Andreas TeufelDepartment of Medicine II, Medical Faculty Mannheim, Heidelberg University, 68167 Mannheim, Germany.
Matthias P A EbertDepartment of Medicine II, Medical Faculty Mannheim, Heidelberg University, 68167 Mannheim, Germany.
Katja Breitkopf-HeinleinDepartment of Medicine II, Medical Faculty Mannheim, Heidelberg University, 68167 Mannheim, Germany.ORCID 0000-0002-1814-4796
Heidelberg University · DEFriedrich-Alexander-Universität Erlangen-Nürnberg · DEGerman Cancer Research Center · DETechnical University of Munich · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

It was previously shown that Bone Morphogenetic Protein (BMP)-9 is constitutively produced and secreted by hepatic stellate cells (HSC). Upon acute liver damage, BMP-9 expression is transiently down-regulated and blocking BMP-9 under conditions of chronic damage ameliorated liver fibrogenesis in C57BL/6 mice. Thereby, BMP-9 acted as a pro-fibrogenic cytokine in the liver but without directly activating isolated HSC in vitro. Lipopolysaccharide (LPS), an endotoxin derived from the membrane of Gram-negative bacteria in the gut, is known to be essential in the pathogenesis of diverse kinds of liver diseases. The aim of the present project was therefore to investigate how high levels of BMP-9 in the context of LPS signalling might result in enhanced liver damage. For this purpose, we stimulated human liver sinusoidal endothelial cells (LSEC) with LPS and incubated primary human liver myofibroblasts (MF) with the conditioned medium of these cells. We found that LPS led to the secretion of factors from LSEC that upregulate BMP-9 expression in MF. At least one of these BMP-9 enhancing factors was defined to be IL-6. High BMP-9 in turn, especially in combination with LPS stimulation, induced the expression of certain capillarization markers in LSEC and enhanced the LPS-mediated induction of pro-inflammatory cytokines in primary human macrophages. In LSEC, pre-treatment with BMP-9 reduced the LPS-mediated activation of the NfkB pathway, whereas in macrophages, LPS partially inhibited the BMP-9/Smad-1 signaling cascade. In vivo, in mice, BMP-9 led to the enhanced presence of F4/80-positive cells in the liver and it modulated the LPS-mediated regulation of inflammatory mediators. In summary, our data point to BMP-9 being a complex and highly dynamic modulator of hepatic responses to LPS: Initial effects of LPS on LSEC led to the upregulation of BMP-9 in MF but sustained high levels of BMP-9 in turn promote pro-inflammatory reactions of macrophages. Thereby, the spatial and timely fine-tuned presence (or absence) of BMP-9 is needed for efficient wound-healing responses in the liver.

Indexed as

AnimalsCells, CulturedCytokinesDown-RegulationEndothelial CellsGrowth Differentiation Factor 2HepatocytesInflammationInflammation MediatorsLipopolysaccharidesLiverMice, Inbred C57BLCytokinesGrowth Differentiation Factor 2Inflammation MediatorsLipopolysaccharidesBMP-9capillarizationHSCIL-6kupffer cellsliverLPSLSECmacrophagesmyofibroblasts

Identifiers

PMID32143367
PMCPMC7140468
OpenAlexW3010441143

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.